Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.60 |
| ▸ | FLT4 | P35916 | 4/20 | 0.60 |
| ▸ | KDR | P35968 | 4/20 | 0.60 |
| ▸ | KIT | P10721 | 2/20 | 0.60 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.57 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.56 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.55 |
| ▸ | GSK3B | P49841 | 3/20 | 0.54 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126400 | 1.00 | FLT3 (0.60) | FLT3FLT4KDRKITALK | |
| SCHEMBL4125272 | 0.93 | FLT3 (0.70) | FLT3FLT4KDRKITALK | |
| SCHEMBL4132694 | 0.93 | FLT3 (0.70) | FLT3FLT4KDRKITALK | |
| SCHEMBL4005915 | 0.91 | FLT3 (0.65) | FLT3FLT4KDRKITALK | |
| SCHEMBL5004992 | 0.91 | FLT3 (0.65) | FLT3FLT4KDRKITALK | |
| SCHEMBL27465416 | 0.89 | ALK (0.58) | FLT3FLT4KDRKITALK | |
| SCHEMBL399276 | 0.87 | FLT3 (0.71) | FLT3FLT4KDRKITALK | |
| SCHEMBL10091916 | 0.87 | FLT3 (0.71) | FLT3FLT4KDRKITALK | |
| SCHEMBL396165 | 0.86 | KDR (0.65) | FLT3KDRKITTLK2AURKB | |
| SCHEMBL10091917 | 0.86 | KDR (0.65) | FLT3KDRKITTLK2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | claimed |
| EP-1814545-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-06-10 | — | — | EP | disclosed |
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-11 | — | — | US | disclosed |
| EP-1814545-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006052936-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221192-A1 | Compounds and Compositions as Protein Kinase Inhibitors | BMX, FRK, PTK2B | FLT3 93/4885FLT4 323/4885KDR 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.